Introduction
Hypertriglyceridemia is an independent and predictive risk factor for atherosclerosis and a key feature of the metabolic syndrome [1-3].
The gene encoding apolipoprotein (apo) APOA5 is recognized as a potential determinant of plasma levels of triglyceride (TG) and TG-rich lipoproteins in mice [4] .
Indeed, overexpression of APOA5 in genetically-modified mouse models consistently leads to reduction in circulating TG concentrations, whereas apoAV deficiency is associated with hypertriglyceridemia [5, 6] . In vitro and in vivo experiments in mice support a role for apoAV in the potentiation of lipoprotein lipase (LPL) activity [7] [8] [9] .
LPL is a central player in determining plasma TG levels, as LPL catalyses the hydrolysis of the hydrophobic core of TG-rich lipoproteins (TRL), including chylomicrons and VLDL. In addition, apoAV has been proposed to enhance VLDL remnant removal by facilitating particle binding to the LDL receptor and interaction of these particles with the LDL receptor-related protein (LRP) and mosaic type-1 receptor (SorLA) [10, 11] Fibrates are lipid-modifying agents which are widely employed in the treatment of hypertriglyceridemia. Thus, pharmacological activation of the nuclear receptor peroxisome proliferator-activated receptor-α (PPARα, NR1C1) by fibrates lowers plasma TG levels not only by increasing conversion of fatty acids to acyl-CoA derivatives and fatty acid oxidation (β-oxidation), but in addition, by stimulating intravascular LPL-mediated lipolysis of TRL [12] [13] [14] . Following heterodimerization of activated PPARα with the retinoid X receptor (RXR), the nuclear receptor complex binds to peroxisome proliferator response elements (PPREs). As a direct consequence, expression of target genes implicated in fatty acid metabolism (L-FABP, mitochondrial 3-hydroxy-3-methylglutaryl-Coenzyme A synthase) and β-oxidation 
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diet rich in polyunsaturated fatty acids or rosiglitazone, both of which are PPARγ activators, increased Apoa5 mRNA levels in livers of obese and insulin-resistant Zucker rats, but tended to diminish both liver and plasma apoAV. However, they also observed a lack of increase in mRNA levels in primary rat hepatocytes treated with PPAR-α or -γ specific agonists, thereby suggesting that rat Apoa5 may be insensitive to stimulation by PPAR agonists, and that the effects of rosiglitazone in Zucker rats are not directly mediated by PPARγ [27] .
In the present study, we evaluated the question as to whether the human and murine APOA5 genes could be differentially regulated by fibrates. We confirmed that the human APOA5 promoter activity is up-regulated following PPARα and fenofibrate treatment in a hepatic cell line. In contrast, the proximal promoter region of the mouse Apoa5 gene was not responsive. In vivo analysis of mice transgenic for the human APOA5 gene (hAPOA5-mice) confirmed these results. Indeed, short term oral gavage of hAPOA5-mice with fenofibrate resulted in a dose-dependent increase of human APOA5 mRNA levels in the liver, whereas those of mouse Apoa5 were concomitantly slightly down-regulated. These data establish that hepatic expression of the mouse and human APOA5 genes is regulated in an opposing manner by fibrates in vivo, and further highlight a critical difference in the regulation of TRL metabolism between mice and humans. 2-3 month old hAPOA5 male mice and wild-type control male littermates were given an oral gavage of 0.2 ml fenofibrate (Sigma) for five days, either once daily at a dose of 100 mg/kg or twice a day at a dose of 125 mg/kg. hAPOA5 transgenic and control non-treated groups received 0.2 ml of vehicle only (0.5% hydroxypropyl methylcellulose, 1% Tween 80). Four hours after the last dose, blood was collected under isoflurane anaesthesia. The animals were then sacrificed by cervical dislocation and livers were collected, rinsed in ice-cold PBS, and snap-frozen in liquid nitrogen.

Materials and methods
Animal protocols--
RNAs were prepared from frozen tissue specimens using TRIzol reagent (Invitrogen). 
Plasma and lipid analyses -
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Statistical analysis.
The statistical significance of the differences between groups was evaluated using the unpaired two-tailed Student t-test. P<0.05 was considered significant. (Fig 3A) . Comparatively, mouse Apoa5 gene expression was decreased similarly (20%) at the two fenofibrate doses in both WT and hAPOA5-mice ( Fig 3B) . As a control for the efficacy for short term fenofibrate treatment, we quantified the level of expression of genes known to be either repressed or activated by PPARα. Thus, we observed that fenofibrate treatment decreased the steady state mRNA levels of both mApoa1 (Fig3C) and mApoc3 (Fig 3D) . In contrast, mLpl ( Fig   3F) and mAcox (Fig.3E ) mRNA levels were strongly upregulated in fenofibrate-fed mice. For all these genes, the effects were comparable in both WT and hAPOA5-mice.
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Results
Presence of a functional PPRE in the proximal
Taken together, these results demonstrate an inverse response of the mouse and human APOA5 genes to PPARα agonist treatment, in which transcription of the human gene is activated in vivo, whereas hepatic mRNA levels of the murine ortholog are downregulated in response to fenofibrate treatment.
Impact of fenofibrate treatment on plasma lipid and lipoprotein levels in WT and hAPOA5 mice-
The impact of a 5-day fibrate treatment in both WT and hAPOA5-mice on plasma lipid and lipoprotein levels was evaluated at the 250 mg/kg dosage. Lipid concentrations were determined at the time of sacrifice, which was performed 4-h after the final gavage of non-fasted mice. Plasma TG levels were lower in hAPOA5-mice as compared to WT mice (Fig. 4A) , as previously reported [5] . In addition, a slight and similar reduction in plasma TG levels was observed in both drug treatedgroups, but this reduction did not reach statistical significance. Surprisingly, plasma total cholesterol (TC) (Fig. 4B ) levels were found to be statistically lower in hAPOA5-mice than in WT untreated-mice. Plasma TC was equally found to be lower in
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fenofibrate-fed hAPOA5-mice as compared to untreated-hAPOA5-mice; such a reduction was not observed in the WT group. However, fenofibrate treatment markedly and similarly modified the distribution of lipoprotein cholesterol in both WT and hAPOA5-mice. Indeed, cholesterol content was reduced in fractions corresponding to HDL particles of normal size, with appearance of larger HDL particles (Fig. 4C) . Such specific change in HDL particle distribution is, in all likelihood, a direct consequence of down-regulation of hepatic scavenger receptor SR-BI expression at the protein level by fibrates which has been previously reported in mice [33] . Indeed, reduced expression of SR-BI consistently results in the appearance of larger HDL, rich in cholesterol, but equally in elevation of plasma levels of HDL-C (and plasma TC) in mice [28] . In the present study, the concomitant marked reduction of mouse APOA1 gene expression following fenofibrate-250 treatment in the WT group (Fig. 3C ) most likely masked the HDL-C raising effect of knockdown expression of SR-BI; thus resulting in no net change in plasma TC levels ( Fig. 4B ) but in the presence of large HDL particles and a decrease in the level of regularly sized HDLs (Fig. 4C) . Hepatic mRNA levels of the mouse Apoa1 and Apoc3 genes were markedly reduced in response to oral gavage with fenofibrate. This effect, which was dose-dependent ( Fig. 3CD) , may result from PPARα-mediated induction of the nuclear receptor Reverbα [20, 41] . Indeed, the presence of a response element for this repressor in the promoters of rodent Apoa1 [42] and Apoc3 genes support this hypothesis. The sequence motifs for Rev-erbα and the nuclear hormone receptor RORα are closely related [43] which explains that the Rev-erbα response element present in the apoa1 gene is also a RORα element [42, 44] . Human APOA5 is a target gene for ROR
through binding to the half-core AGGTCA DR1/PPRE site [45] , whereas mouse apoa5 is not, due to a nucleotide difference in the half-core site which prevents RORα binding to the mouse promoter [32] . Consistently, mouse Apoa5 gene expression is not affected in the staggerer mutant mouse which carries a deletion in the gene encoding for RORα [32] . Thus, the modest decrease of mApoa5 mRNA levels that we observed in the livers of fenofibrate-fed mice is unlikely to result from PPAR-induced Rev-erbα repression mechanism, as most likely occured for the Apoa1 and Apoc3
genes. This hypothesis is consistent with the fact that the activity of the mouse Apoa5 promoter was not repressed by PPARα and fenofibrate treatment in transient transfection assays (Fig. 2 ).
In conclusion, this study provides additional evidence that extrapolation from mouse to man of experimental findings involving the pharmacological action of fibric acid or their derivatives on lipid metabolism must be conducted with considerable caution.
Nonetheless, comparison of hAPOA5-mice with non-transgenic controls in response to treatment with PPAR agonists may prove useful in deciphering the physiological significance of apoAV in the regulation of TG metabolism in fasting or non-fasting conditions, and equally in normo-or hyperlipidemic contexts. In the latter context, cross-breeding of hAPOA5-mice with the ApoE2 knock-in mouse model recently allowed demonstration of an atheroprotective effect of hapoAV overexpression on a background of mixed dyslipidemia; this effect was further enhanced upon hAPOA5 gene activation by fenofibrate [40] . Finally, such studies may highlight a potential mechanism by which apoAV could impact HDL-C levels. In this respect, crossbreeding of hAPOA5-mice with the recently-described hyperlipidemic E3L.CETP mouse model [46] , in which the dual ability of fibrates to potently reduce
plasma TG and concomitantly increase HDL-C was clearly demonstrated, may constitute an interesting approach.
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